Novo Nordisk A/S vs UBS Group AG: Strategic Comparison

This in-depth comparison examines Novo Nordisk A/S and UBS Group AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novo Nordisk A/S on its own, evaluating UBS Group AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novo Nordisk A/S and UBS Group AG is widest.

On the headline numbers, Novo Nordisk A/S reports annual revenue of $46.0B against $47.7B for UBS Group AG, while their respective market capitalizations stand at $550.0B and $167.8B. Novo Nordisk A/S is headquartered in Denmark and UBS Group AG operates from Switzerland, and those different home markets shape how each company competes.

Novo Nordisk A/S: Novo Nordisk A/S is a public company listed on NYSE under ticker NVO. Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.

UBS Group AG: UBS is less a traditional bank than a global private-wealth platform with a large Swiss banking base and selective investment banking capabilities. The Credit Suisse acquisition increased scale but made execution the central story.

Novo Nordisk A/S and UBS Group AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novo Nordisk A/S and UBS Group AG.

Novo Nordisk A/S business model: Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.

UBS Group AG business model: UBS makes money from wealth management fees, advisory, lending, Swiss retail and corporate banking, asset management fees, investment banking advisory and capital markets activity, and trading. Wealth management provides the strategic core because asset-based fees recur as long as client assets remain on the platform.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novo Nordisk A/S stack up against those of UBS Group AG.

Novo Nordisk A/S competitive advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.

UBS Group AG competitive advantage: UBS's advantage is the combination of Swiss banking trust, global ultra-high-net-worth coverage, more than USD 7 trillion in invested assets, and the ability to serve clients across wealth management, lending, capital markets, and asset management.

Future prospects matter as much as current results. The growth strategies below explain how Novo Nordisk A/S and UBS Group AG each plan to expand from here.

Novo Nordisk A/S growth strategy: Novo Nordisk A/S's growth strategy centers on this advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.

UBS Group AG growth strategy: UBS is focused on integrating Credit Suisse, reducing duplicate costs, expanding global wealth management relationships, using technology to improve advisor productivity, growing asset management mandates, and keeping the investment bank focused on capital-light advisory and markets strengths.

A closer look at the financial trajectory of Novo Nordisk A/S and UBS Group AG rounds out the comparison.

Novo Nordisk A/S: Novo Nordisk A/S reported FY2025 revenue of DKK 309.064B (about $46.0B) and net income of DKK 102.434B (about $15.2B).

UBS Group AG: UBS Group reported USD 7.8 billion in 2025 net profit attributable to shareholders and a CET1 ratio of 14.4%. UBS AG consolidated total revenues were USD 47.7 billion, up from USD 42.3 billion in 2024, as Credit Suisse consolidation and client activity reshaped the revenue base.